Taiwan is undergoing a boom in biotechnology, rewarding years of dedicated effort from its stakeholders. More and more locally-developed drugs are entering late-stage clinical trials, and new companies, service providers and manufacturing facilities are emerging to fill rapidly growing industry needs. Overseas interest is picking up as well, with licensing, partnering and investment agreements at an all-time high. The total market capitalization of local publicly-listed biotech companies has soared, increasing 700 percent since 2008’s capital market crash, rewarding stakeholders for their patience and support.
The biotech industry in Taiwan has a set of unique characteristics and strengths that make it an appealing prospect to the global life science community looking for partnership, investment or licensing opportunities. These include:
Vibrant VC industry and capital markets
Strong business and cultural ties to the Greater China market
World-class clinical trial capability
Transparent legal and business environment, with strong IP protection
Well established private-public partnerships with deep innovation pipelines
Highly-educated, motivated and cost-effective workforce
Executives with overseas training, global view and Big Pharma experience
Strong government support, subsidies and tax breaks
As healthcare is moving from a "one size fits all" model towards a more personalized approach, bringing together Taiwan’s newest diagnostic tools with precision therapeutics, existing strengths in ICT and device industries means that Taiwan is well placed to excel in this evolving healthcare ecosystem.
Save the dates and join us to experience the vibrancy, innovation and inspiration of Taiwan's biotech industry and explore the tremendous opportunities on offer at BioTaiwan 2017!
Dr. Johnsee Lee,
Chairman, BioTaiwan 2017 Organizing Committee;
Chairman, Taiwan BIO
Date: July 18 (Wed.) - July 22 (Sun.)
Venue: TWTC Nangang Exhibition Hall (No. 1, Jingmao 2nd. Rd., Nangang Dist., Taipei City)